Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001209191-22-061697
Filing Date
2022-12-16
Accepted
2022-12-16 17:00:34
Documents
1
Period of Report
2022-12-14

Document Format Files

Seq Description Document Type Size
1 FORM 4 SUBMISSION doc4.html 4  
1 FORM 4 SUBMISSION doc4.xml 4 5589
  Complete submission text file 0001209191-22-061697.txt   6941
Mailing Address 201 BROOKLINE AVENUE SUITE 601 BOSTON MA 02215
Business Address 201 BROOKLINE AVENUE SUITE 601 BOSTON MA 02215 (978) 501-3026
Verve Therapeutics, Inc. (Issuer) CIK: 0001840574 (see all company filings)

EIN.: 824800132 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address 500 TECHNOLOGY SQUARE CAMBRIDGE MA 02139
Business Address
Bellinger Andrew (Reporting) CIK: 0001864116 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-40489 | Film No.: 221468670